Nemvaleukin alfa

奈沃白介素 α

Report date: 2025/08/29 20:01:31

Base Information

Drug NameNemvaleukin alfa

Drug Alias NameNemvaleukinRDB-1450RDB-1419ALKS-4230

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Recombinant protein > Recombinant cytokines

Mechanisms of ActionInterleukin-2 receptor alpha chain agonists

TargetsInterleukin-2 receptor alpha chain

Therapy Area/IndicationsSkin MelanomaSolid tumoursFallopian Tube Neoplasms +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumCanada +[16]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAlkermes Plc

China Registration ClassN/A

Develop Information

Active CompaniesMural Oncology Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursSquamous Cell Carcinoma of Head and Neck

Inactive IndicationsSkin MelanomaFallopian Tube NeoplasmsOvarian Neoplasms +[5]

Other Information

ATC CodeN/A